Gut microbiome modulates efficacy of immune checkpoint inhibitors

Abstract Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable e...

Full description

Bibliographic Details

Published in:	Journal of Hematology & Oncology
Main Authors:	Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu, Kongming Wu
Format:	Article
Language:	English
Published:	BMC 2018-03-01
Subjects:	Gut microbiome Immunotherapy PD-1/PD-L1 CTLA-4 ICIs resistance
Online Access:	http://link.springer.com/article/10.1186/s13045-018-0592-6